Telitacicept Efficacy for Relapsing Lupus Nephritis: A Retrospective Cohort Study

A retrospective cohort study of 40 adults with relapsing lupus nephritis, conducted from 2021 to 2024. The data likely contains laboratory indicators, renal remission status, SLEDAI-2K scores, glucocorticoid dosages, and renal flare incidence, used to evaluate the add-on therapy telitacicept. The dataset was authored by Cui Wang and shared under a CC-BY-4.0 license.

Use Cases

• Compare complete renal remission rates between treatment groups based on the described study results.
• Analyze the relationship between add-on telitacicept and reductions in 24-hour urinary protein as mentioned in the description.
• Model predictors of early complete renal remission using the multivariate regression analysis described.
• Assess the safety profile of a treatment by comparing adverse event incidence between cohorts.

Strengths

• The study design includes a control group (n=20) and a treatment group (n=20) for comparative analysis.
• Clinical outcomes are tracked at multiple time points (1, 3, 6, 9, and 12 months) as described.
• Analysis includes multivariate Cox regression to identify predictors of complete renal remission.

Limitations

• Row count and specific column definitions are unknown, requiring manual inspection after download.
• The dataset is very small at 38.4 KB, indicating limited scope and sample size.
• The geographic origin of the patient cohort is not specified, which may limit generalizability.

Provenance

Source

figshare, author Cui Wang.

Collection Method

Retrospective cohort study of identified patients from 2021 to 2024.

Time Range

2021 to 2024

Freshness

Last updated 2026-05-22 06:09:07.